Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Eli Lilly and Company is conducting a Phase 3b study titled A Phase 3b, Randomized, Multicenter, Controlled Study of Mirikizumab and Placebo or Mirikizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight. The study aims to evaluate whether the combination of mirikizumab and tirzepatide can effectively reduce symptoms of ulcerative colitis (UC) and achieve significant weight loss in participants compared to mirikizumab and placebo.
Intervention/Treatment: The study tests two interventions: mirikizumab, administered both intravenously and subcutaneously, and tirzepatide, administered subcutaneously. The goal is to assess their combined effect on UC symptoms and weight management.
Study Design: This interventional study is randomized with a parallel assignment model. It uses double masking, meaning both participants and investigators are unaware of whether tirzepatide or placebo is administered alongside mirikizumab. The primary purpose is treatment-focused.
Study Timeline: The study began on June 26, 2025, with an estimated primary completion and overall completion timeline extending up to 61 weeks. The last update was submitted on July 22, 2025, indicating active recruitment.
Market Implications: This study could significantly impact Eli Lilly’s stock performance and investor sentiment, especially if the combination therapy proves effective. Success could position Eli Lilly favorably against competitors in the UC treatment market, potentially increasing market share and revenue.
The study is ongoing, and further details are available on the ClinicalTrials portal.